Anne Portwich, PhD, has been with LSP since 2001. She is a Partner in LSP’s Amsterdam office. Her prime focus and responsibility within LSP is to invest in private companies. Over the years, she has been responsible for investments in numerous portfolio companies of LSP, such as Sapiens (acquired by Medtronic in 2014), Nexstim (IPO in 2014), and ActoGeniX (acquired by Intrexon in 2015).
When the first LSP Health Economics Fund was launched in 2012, she became part of the investment team managing this fund, leading investments in companies such as ViCentra, MedEye, Vivasure Medical and Neuravi (acquired by Johnson & Johnson in 2017). She also played an pivotal role in raising the LSP Health Economics Fund 2 in 2017, the largest European fund dedicated to medical technology with a fund size of € 280 million. Prior to joining LSP, Anne was a Scientist and Project Leader at OctoPlus, a Dutch company offering advanced research services to pharmaceutical and biotechnology companies. She obtained an MSc in biochemistry from the University of Hanover and received her PhD from the Max Planck-Institute of Marine Microbiology in Bremen. Anne lives near Leiden with her husband and son.
To contact Anne directly, email email@example.com or call +31 (0) 20 664 55 00.